‘Should I give up soy?’ The question returns in every consultation with a patient with hormone-dependent breast cancer. The fear was born of a confusion: soy isoflavones bind to oestrogen receptors, so they ‘must act as oestrogen’. Twenty years of data have settled it: that is not what they do.
Isoflavones: modulators, not oestrogens
Soy isoflavones (genistein, daidzein, glycitein) are phytoestrogens, but the term is misleading: they are not weak oestrogens adding to oestrogens. They are selective receptor modulators (SERM-like): they bind to receptors but with a different affinity and a different effect depending on the tissue.
The decisive point: isoflavones bind preferentially to the ER-β receptor, whose effect is rather anti-proliferative in the breast, whereas oestradiol binds ER-α, which is proliferative. The phytoestrogen occupies the receptor without sending the same signal: it is a competitor more than a fuel.
What the data say about the ER+ breast
The large observational studies tested the hypothesis on real patients:
The Asian studies (Shanghai Breast Cancer Survival Study, Chinese and Japanese cohorts) show that breast cancer survivors consuming the most soy have reduced recurrence and mortality compared with non-consumers. The effect is dose-dependent up to normal dietary doses.
Western cohorts confirm: dietary soy consumption after ER+ breast cancer is not associated with increased recurrence; meta-analyses conclude safety and a possible modest protection.
The lifetime effect: protection is stronger in women who have eaten soy since childhood; starting in adulthood produces a lesser but not harmful effect.
Dietary doses versus concentrated supplements
The crucial distinction: food and extract are not the same thing.
Dietary doses (tofu, tempeh, edamame, miso, soy milk) provide 20-80 mg of isoflavones a day in traditional Asian usage; it is at these doses that the safety and protection data apply.
Concentrated supplements (purified isoflavones, extracts at 100-200 mg per capsule) deliver supraphysiological doses whose safety is not established in ER+ patients. The recommendation of oncologists and learned societies: dietary soy is safe; isoflavone supplements are to be avoided in the hormone-dependent patient.
| Form | Isoflavone dose | Safety in the ER+ patient |
|---|---|---|
Tamoxifen and soy: the real interaction
Tamoxifen is itself a receptor modulator (a true SERM). The concern: isoflavones might compete with tamoxifen at the receptor. The real data go the other way: observational studies show that soy consumption in patients on tamoxifen does not weaken the efficacy of the treatment; some suggest a favourable additive effect.
The only precaution that remains: very high supplemental doses, and the particular case of equol metabolism (only a third of Westerners produce equol, the active metabolite of daidzein, via their microbiome).
The TCM reading: soy, neutral and slightly cool
Chinese dietetics has known soy for two thousand years (the da dou, 大豆). Its reading: neutral to slightly cool, sweet, tonifying the Spleen and producing fluids. Tofu is read as cool and Yin-nourishing; fermented tempeh and miso are more transformed and better tolerated by cold terrains.
The TCM reading of the controversy joins biomedicine: dietary soy is neither an aggressive tonic nor a food to ban; it is a neutral protein source, whose moderation and fermented form are the wisest. In the menopause and the Yin-deficient terrain, dietary soy nourishes Yin without heating.
What requires medical advice
The patient with hormone-dependent cancer should discuss her consumption with her oncologist, especially if she is considering isoflavone supplements. Dietary soy has no documented contraindication for her; concentrated supplements and very high doses are to be avoided in the absence of sufficient safety data.
FAQ: soy and hormones
Does soy enlarge men’s breasts?
Not at dietary doses: reported cases involved extreme consumption (several litres of soy milk a day). At dietary doses, no feminising effect is documented.
Is soy safe after ER+ breast cancer?
Yes at dietary doses: studies show safety and a possible modest protection. It is concentrated isoflavone supplements that are discouraged.
Should fermented soy be preferred?
Fermented soy (tempeh, miso, natto) is traditionally better tolerated and fermentation increases isoflavone bioavailability. It is a good option, but unfermented tofu remains safe.
Does soy interfere with the thyroid?
At normal dietary doses, in people with sufficient iodine intake, no. Isoflavones can slightly inhibit thyroid peroxidase in vitro, but no clinical effect is documented in euthyroid, well-iodised people.
Soy, the food that fear overtook
The soy controversy is a textbook case: a biochemical property (binding the receptor) was read as a danger before data on real patients described it as a protective modulation. The food is safe; the concentrated extract is another matter; and the ER+ patient can put tofu back on her plate.
To go further
Yin Shi ecosystem resources directly related to this article.